Table 2 Cervical, anal and oral HPV prevalence for the study population (percentages refer to the total of each age group)
From: Cervical, anal and oral HPV detection and HPV type concordance among women referred for colposcopy
|  | Cervical [n = 118 (100.0%)] | Anal [n = 118 (100.0%)] | Oral [n = 118 (100.0%)] |
|---|---|---|---|
HRHPV | 65 (55.1%) | 64 (54.2%) | 3 (2.5%) |
LRHPV | 14 (11.9%) | 11 (9.3%) | 0 (0.0%) |
HR+LRHPV | 9 (7.6%) | 23 (19.5%) | 0 (0.0%) |
HPV16/18 | 26 (22.0%) | 16 (13.5%) | 2 (1.7%) |
HRHPV16 | 26 (22.0%) | 11 (9.3%) | 2 (1.7%) |
HRHPV18 | 0 (0.0%) | 5 (4.2%) | 0 (0.0%) |
HRHPV31 | 16 (13.6%) | 18 (15.3%) | 0 (0.0%) |
HRHPV33 | 7 (5.9%) | 6 (5.1%) | 0 (0.0%) |
HRHPV35 | 3 (2.5%) | 3 (2.5%) | 0 (0.0%) |
HRHPV39 | 2 (1.7%) | 0 (0.0%) | 0 (0.0%) |
HRHPV45 | 2 (1.7%) | 1 (0.8%) | 0 (0.0%) |
HRHPV51 | 9 (7.6%) | 12 (10.2%) | 0 (0.0%) |
HRHPV52 | 9 (7.6%) | 5 (4.2%) | 0 (0.0%) |
HRHPV53 | 7 (5.9%) | 20 (16.9%) | 1 (0.8%) |
HRHPV56 | 2 (1.7%) | 1 (0.8%) | 0 (0.0%) |
HRHPV58 | 6 (5.1%) | 6 (5.1%) | 0 (0.0%) |
HRHPV59 | 2 (1.7%) | 4 (3.4%) | 0 (0.0%) |
HRHPV66 | 1 (0.8%) | 8 (6.8%) | 0 (0.0%) |
HRHPV68 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
HRHPV70 | 0 (0.0%) | 7 (5.9%) | 0 (0.0%) |
HRHPV73 | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) |
HRHPV82 | 2 (1.7%) | – | – |
LRHPV6 | 4 (3.4%) | 10 (8.5%) | 0 (0.0%) |
LRHPV11 | 1 (0.8%) | 1 (0.8%) | 0 (0.0%) |
LRHPV40 | 1 (0.8%) | 4 (3.4%) | 0 (0.0%) |
LRHPV42 | 7 (5.9%) | 5 (4.2%) | 0 (0.0%) |
LRHPV44 | 0 (0.0%) | 2 (1.7%) | 0 (0.0%) |
LRHPV54 | 2 (1.7%) | 2 (1.7%) | 0 (0.0%) |
LRHPV61 | 5 (4.2%) | 5 (4.2%) | 0 (0.0%) |
LRHPV62 | 1 (0.8%) | 3 (2.5%) | 0 (0.0%) |
LRHPV65 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
LRHPV71 | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) |
LRHPV81 | 3 (2.5%) | 5 (4.2%) | 0 (0.0%) |
LRHPV83 | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) |
LRHPV84 | 1 (0.8%) | 3 (2.5%) | 0 (0.0%) |